Intravacc

Today we'd like to introduce the next member of our newly appointed Industry Advisory Board (IAB): Manon Cox. Dr. Manon Cox is the founder and CEO of NextWaveBio, a biotechnology company in East-Haven Connecticut. She is also director of Vaxxas, and GPN vaccines, both clinical stage vaccine development companies. Prior to these roles, Dr. Cox was President and CEO at Protein Sciences Corporation, a biotechnology company starting in 1998 until its acquisition by Sanofi in 2018 where she led the development of Flublok, the only FDA-approved recombinant influenza vaccine. Dr. Cox currently serves on the Board of the Netherlands America Foundation (NAF) and Board of the International Society for Vaccines (ISV) and was elected incoming President for 2024-2025, with the expectation to be President of the Society during 2026-2027. She also serves on various Scientific Advisory Committees including Epivax Therapeutics and Omnicyte. She is the recipient of numerous accolades due to her trailblazing work in innovation and influenza. In 2014, she was conferred with a Doctorate in Humane Letters honoris causa from St. Joseph University, a testament to her profound impact on the field. Later, she was given the prestigious Woman of Innovation award from the Connecticut Technology Council, alongside her induction as a fellow in the International Society of Vaccines in 2015. Follow our LinkedIn page to stay up to date on the latest Intravacc news, including the introductions of the other IAB members. #Intravacc #Bilthoven #CDMO #Vaccines

Today we'd like to introduce the second member of our newly appointed Industry Advisory Board (IAB): albert Osterhaus. Prof. Dr. Ab Osterhaus, former head of the Department of Viroscience at Erasmus MC Rotterdam, has a long track record as researcher and project leader, bringing world-leading scientists together in the field of virology, immunology and epidemiology. His research accomplishments include the discovery of more than 80 viruses of humans and animals, enabling health authorities like the WHO to effectively combat disease outbreaks like SARS. In addition to his work as researcher, Ab is active as the Founding Director of the Center of Infection Medicine and Zoonosis Research (RIZ) and Cofounder of both ViroNative and CR2O, focusing on effective testing and refinement of diagnostic tools, as well as preventive and therapeutic intervention strategies. Follow our LinkedIn page to stay up to date on the latest Intravacc news, including the introductions of the other IAB members. #Intravacc #Bilthoven #CDMO #Vaccines

Last week, we announced the inauguration of our Industry Advisory Board (IAB). Today, we'd like to introduce the first member and Chairman of the board: Prof. Eric Claassen. Prof. Dr. Eric Claassen successfully founded and sold numerous Dutch Biotech firms, among which Viroclinics Biosciences B.V., Genewity B.V., Rabian B.V. and ViroNative B.V. In addition, Eric is an investor in over 15 Dutch Biotech startups and has been Chairman of advisory boards for various companies, including a tenure as Chairman of NATO PG32 on “Handheld detection of Biological Weapons”. Eric has held positions as a professor of both Immunology and Valorisation at Erasmus MC, during which he became the first Biopartner professor “Entrepreneurship in the Life Sciences” on behalf of the Ministry of Economic Affairs at the Vrije Universiteit of Amsterdam. For Eric's full resume see: https://lnkd.in/evD2BQuD Follow our LinkedIn page to stay up to date on the latest Intravacc news, including the introductions of the other IAB members. #Intravacc #Bilthoven #CDMO #Vaccines

We are excited to announce the launch of our newly established Industry Advisory Board (IAB)! The IAB is set up to strengthen Intravacc’s business strategy, foster closer ties with the industry, and capitalize on emerging developments and opportunities. This esteemed board consists of five distinguished industry leaders: • Prof. Eric Claassen (Chairman) • albert Osterhaus • Manon Cox • Peter Hermans • Pieter Harmen (Harry Flore We are delighted to welcome these accomplished professionals to our company. Their expertise will be invaluable in shaping our strategic direction and enriching our business expertise. In the coming weeks, we will introduce each member in more detail – stay tuned. #Intravacc #Bilthoven #CDMO #Vaccines

It's still three months away, but be sure to mark it on your calendars: April 21-24 Intravacc will be exhibiting at The World Vaccine Congress in Washington, D.C. to showcase how our platforms and services can help you take your vaccine concept to the next stage. There is still time to register, will we see you there? Follow our LinkedIn page to stay up-to-date on the latest Intravacc news. #Intravacc #Bilthoven #CDMO #Vaccines #WVCDC #WorldVaccineCongress

Happy holidays from all of us at Intravacc May this holiday season bring you and your loved ones peace, joy, and cherished moments. Merry Christmas and a prosperous 2025!

Are you visiting Vaccines Summit 2024 and interested in conjugate vaccins? Then you are in luck! Our Director Business Development Robert van der Put, PhD is co-chairing and presenting during the Conjugate Vaccine Session this morning. In his talk he'll highlight the benefits that conjugation of your antigenic peptide to Intravacc's Outer Membrane Vesicles can offer. So if you've ever wanted to learn more about the possibilities of conjugation vaccines, this is your chance to hear it from the expert! #Intravacc #Bilthoven #CDMO #Vaccines #Conjugation #Con_Vacc #VaccinesSummit

Ready for the final day of the 30th BIO-Europe, so close off this year's event with a visit to the Intravacc stand. As a CDMO specialized in vaccine development we have all the tools to help you progress your vaccine concept to the next phase. Whether it's development, scale-up or analyses we're here to support you work! Our BD team is more than happy to assist you at booth #12 #Intravacc #Bilthoven #CDMO #Vaccines #OMV #OMV_Vacc #Cell_based #Cell_Vacc #Conjugation #Con_Vacc #BIOEurope

Today, at the second day of BIO-Europe we had the pleasure of welcoming the Dutch Minister for Foreign Trade and Development Aid Reinette Klever | Minister BHO together with the president of The Confederation of Netherlands Industry and Employers Ingrid Thijssen as well as the Ambassador for The Netherlands in Sweden Joost Reintjes. During the visit we discussed the important role of Dutch Biotech companies on global health. As a leading CDMO specializing in #vaccines Intravacc is proud to do its part. Many thanks to Robbert Wever, Annemiek Verkamman and Dora Menting from hollandbio for the coordination. #Intravacc #Bilthoven #CDMO #Vaccines #BIOEurope

Are you ready for day 1 of BIO-Europe? We sure are! Developing a vaccine is no small feat. Taking your concept from R&D to phase 1 and beyond can seem like a daunting task, but collaborating with the right people makes it considerably easier. Want to learn about all the ways in which Intravacc can assist your vaccine development? Join us at booth #12 where Program Manager Peter Soema and Director Business Development Robert van der Put, PhD are more than happy to answer your questions. #Intravacc #Bilthoven #CDMO #Vaccines #Conjugation #Con_Vacc #OMV #OMV_Vacc #Cell_based #Cell_Vacc #Ecoli_expression #Eco_Vacc #BIOEurope